Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Renizgamglogene autogedtemcel by Editas Medicine for Beta Thalassaemia: Likelihood of Approval
Renizgamglogene autogedtemcel is under clinical development by Editas Medicine and currently in Phase II for Beta Thalassaemia. According to GlobalData,...
Data Insights
Renizgamglogene autogedtemcel by Editas Medicine for Sickle Cell Disease: Likelihood of Approval
Renizgamglogene autogedtemcel is under clinical development by Editas Medicine and currently in Phase III for Sickle Cell Disease. According to...